Pfizer Inc. said on Wednesday that its COVID-19 vaccine is 95% effective based on the final analysis of clinical data, according to Bloomberg. The efficacy improvement paves the way for U.S. regulatory authorization within days. The news comes a week after the companies reported the vaccine was more than 90% effective.
- Pfizer and BioNTech have gathered the two-month safety follow-up data required by the U.S. Food and Drug Administration, paving the way for emergency authorizations.
- Pfizer and BioNTech vaccine protects people of all ages and ethnicities with no significant safety concerns based on a sample of about 44,000 participants.
- The vaccine efficacy was more than 94 for people older than 65 years.
- About two days ago, Moderna announced its vaccine that was 94.5% effective against coronavirus.
Pfizer stock rose 2.7% in premarket trading while BioNTech rose 7.3% on vaccine news. PFE: NYSE is up 3.22% on premarket, BNTX: NASDAQ is up 6.98% on premarket.
XTB
